Making ATMPs a reality for rare disease patients
European Pharmaceutical Review
FEBRUARY 28, 2024
The implementation of the EU’s Health Technology Assessment Regulation (HTAR) 1 will play a key role in shaping the patient access pathway for ATMPs such as cell and gene therapies. This group now has the challenge of developing methodologies to assess the relative clinical effectiveness of a new therapy.
83 
Let's personalize your content